Françoise Boyer

1.3k total citations
14 papers, 161 citations indexed

About

Françoise Boyer is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Françoise Boyer has authored 14 papers receiving a total of 161 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 9 papers in Hematology and 5 papers in Molecular Biology. Recurrent topics in Françoise Boyer's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Kruppel-like factors research (5 papers). Françoise Boyer is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Kruppel-like factors research (5 papers). Françoise Boyer collaborates with scholars based in France, United States and Italy. Françoise Boyer's co-authors include Mathilde Hunault, Marie‐Christine Rousselet, Marie‐Pierre Moles, Elsa Parot‐Schinkel, Jean‐Jacques Kiladjian, Brigitte Dupriez, A Charbonnier, Bruno Cassinat, Marie Robin and Sylvie François and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Agricultural and Food Chemistry.

In The Last Decade

Françoise Boyer

13 papers receiving 160 citations

Peers

Countries citing papers authored by Françoise Boyer

Since Specialization

Citations

This map shows the geographic impact of Françoise Boyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Françoise Boyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Françoise Boyer more than expected).

Fields of papers citing papers by Françoise Boyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Françoise Boyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Françoise Boyer. The network helps show where Françoise Boyer may publish in the future.

Co-authorship network of co-authors of Françoise Boyer

This figure shows the co-authorship network connecting the top 25 collaborators of Françoise Boyer. A scholar is included among the top collaborators of Françoise Boyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Françoise Boyer. Françoise Boyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF). 2023 ·Journal of Clinical Oncology ·Prithviraj Bose, Sanjay Mohan, Stephen T. Oh, Jason Gotlib, Ellen K. Ritchie, Taizo Shimomura, Haris Ali, Françoise Boyer, Paola Guglielmelli, Anthony M. Hunter, (unknown), Yi Cui, Francis Séguy, (unknown), Francesca Palandri, Masahiro Takeuchi, Jean‐Jacques Kiladjian	3
2	P1022: PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR-LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER-104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS 2023 ·HemaSphere ·Prithviraj Bose, Sanjay Mohan, Stephen T. Oh, Jason Gotlib, Ellen K. Ritchie, Taizo Shimomura, Haris Ali, Françoise Boyer, Paola Guglielmelli, Anthony M. Hunter, (unknown), Yi Cui, Francis Séguy, (unknown), Francesca Palandri, Masahiro Takeuchi, Jean‐Jacques Kiladjian	1
3	Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis 2023 ·Blood ·Sanjay Mohan, Stephen T. Oh, Jean‐Jacques Kiladjian, Masahiro Takeuchi, Jason Gotlib, Ellen K. Ritchie, Taizo Shimomura, Paola Guglielmelli, Anthony M. Hunter, Francesca Palandri, Françoise Boyer, Alessandro Rambaldi, Takehiko Mori, Tomoki� Ito, (unknown), (unknown), Yi Cui, Francis Séguy, (unknown), Prithviraj Bose	3
4	Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10⁹/L to <100 × 10⁹/L) at baseline: the final analysis of EXPAND 2022 ·Therapeutic Advances in Hematology ·Paola Guglielmelli, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Minghui Duan, Haitao Meng, Ling Pan, Guangsheng He, Srđan Verstovšek, Françoise Boyer, Fiorenza Barraco, Dietger Niederwieser, Ester Pungolino, (unknown), Claire Harrison, (unknown), (unknown), (unknown), (unknown), Peter A.W. te Boekhorst, Heinz Gisslinger	9
5	Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis 2022 ·Haematologica ·Sandrine Lemoine, (unknown), Isabelle Quintin‐Roué, Marie‐Christine Rousselet, (unknown), (unknown), (unknown), Françoise Boyer, Corentin Orvain, (unknown), (unknown), (unknown), (unknown), Jean‐Christophe Ianotto, Emmanuelle Génin, Barbara Burroni, Valérie Ugo, Damien Luque Paz, Éric Lippert	8
6	Transfusion-Transmitted Hepatitis A Virus, France, 2018 2021 ·Emerging infectious diseases ·Caroline Lefeuvre, (unknown), Françoise Boyer, (unknown), Lina Mouna, Anne‐Marie Roque‐Afonso, Hélène Le Guillou‐Guillemette, Rafaël Mahieu	7
7	WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis 2018 ·Blood Cells Molecules and Diseases ·(unknown), Jérémie Riou, Françoise Boyer, Anne Bouvier, Alain Zannetti, (unknown), (unknown), (unknown), (unknown), (unknown), Corentin Orvain, Mathilde Hunault, Odile Blanchet, Valérie Ugo, Damien Luque Paz	7
8	Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM) 2016 ·Blood ·Sandra Malak, Pascale Cony‐Makhoul, Jean‐Christophe Ianotto, Dana Ranta, Philippe Rodon, (unknown), Fiorenza Barraco, Françoise Boyer, Katell Le Dû, Loïc Garçon, François Lefrère, Mathieu Wémeau, Valérie Ugo, Jean‐Jacques Kiladjian, Lydia Roy	3
9	Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome 2016 ·Genes Chromosomes and Cancer ·Damien Luque Paz, Aurélie Chauveau, Françoise Boyer, (unknown), (unknown), (unknown), Valérie Seegers, Claude Férec, Cédric Le Maréchal, Paul Guéguen, Éric Lippert, Jean‐Christophe Ianotto, Valérie Ugo	12
10	Long Term Efficacy and Tolerance of Pegylated Interferon Alpha Therapy for Patients with High Risk Essential Thrombocythemia: An Observational Study of the French Intergroup of Myeloproliferative Disorders (FIM) 2014 ·Blood ·Lydia Roy, Jean‐Christophe Ianotto, Joëlle Guilhot, Christian Récher, Laurence Legros, Dana Ranta, Emmanuel Raffoux, Pascale Cony Makhoul, Emmanuel Gyan, Benoît De Renzis, Françoise Boyer, Thierry Muron, Franck E. Nicolini, Kamel Laribi, Jean‐Jacques Kiladjian, Stéphane Giraudier	0
11	Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc 2013 ·Blood ·Marie Robin, Sylvie François, Anne Huynh, Bruno Cassinat, Jacques‐Olivier Bay, Jérôme Cornillon, (unknown), A Charbonnier, Mauricette Michallet, Françoise Boyer, Stéphane Vigouroux, Laure Vincent, Ibrahim Yakoub‐Agha, Raphaël Porcher, Gèrard Socié, Brigitte Dupriez, Jean‐Jacques Kiladjian	44
12	Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis 2010 ·Histopathology ·(unknown), Elsa Parot‐Schinkel, Marie‐Pierre Moles, Françoise Boyer, Mathilde Hunault, Marie‐Christine Rousselet	52
13	Pegylated Interferon Alpha-2a Therapy for Patients with High Risk Essential Thrombocytemia: a Retrospective Analysis on 59 Patients.On Behalf of the French Intergroup of Myeloproliferative Disorders (FIM) 2010 ·Blood ·Lydia Roy, Jean‐Christophe Ianotto, Joëlle Guilhot, Emmanuel Raffoux, Emmanuel Gyan, Benoît De Renzis, Laurence Legros, Jean‐François Viallard, Françoise Boyer, (unknown), Franck E. Nicolini, (unknown), Stéphane Giraudier	2
14	Identification and Formation Pathway of Laccase-Mediated Oxidation Products Formed from Hydroxyphenylureas 2006 ·Journal of Agricultural and Food Chemistry ·Claude Jolivalt, Luc Neuville, Françoise Boyer, Lucien Kerhoas, Christian Mougin	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact